Deferasirox应如何使用？

(Deferasirox, Enrig) is one of the more common drugs in clinical practice. For some patients who require long-term blood transfusions due to diseases, such as patients with thalassemia, Deferasirox (Deferasirox, Enrig) can be chosen for treatment. Patients must pay attention to the scientific nature of medication when taking Deferasirox (Deferasirox, Enrig). So, how should Deferasirox (Deferasirox, Enrig) ​​be used?

Deferasirox dispersible tablets should be taken once daily on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole. Deferasirox (Deferasirox, Enrig) ​​dispersible tablets should not be taken together with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet.

Deferasirox (Deferasirox, Enrig) completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and drink it. The remaining drug must be added to a small amount of water, apple juice or orange juice and mixed well before taking it. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Deferasirox (Deferasirox, Enrig) may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the condition is severe or persistent, the medication should be stopped. The patient's vision or hearing may be affected. While taking medicine, patients with thalassemia are often physically weak, so they should live cautiously in daily life, adapt to cold temperatures, and pay attention to preventing external infections; engage in more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to enhance physical fitness and disease resistance.

In order to ensure that the efficacy of Deferasirox (Deferasirox, Enrig) is better exerted, it should be avoided to combine with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine. Do not administer concurrently with aluminum-containing antacids. Not to be combined with other iron chelation treatments. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold Deferasirox (Deferasirox, Enrig) ​​at least 5 days before performing gallium-67 imaging.

The above is the content of how to take (Deferasirox, Enrego), I hope it can help you!